Single-dose psilocybin treatment for major depressive disorder

JAMA

Peer-Reviewed Publication

JAMA NETWORK

About The Study: In a randomized clinical trial with 104 participants, psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events. These findings add to increasing evidence that psilocybin—when administered with psychological support—may hold promise as a novel intervention for major depressive disorder.

Authors: Charles L. Raison, M.D., of Usona Institute in Fitchburg, Wisconsin, is the corresponding author.

link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.14530)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article 

 https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.14530?guestAccessKey=7ff7bcd4-634a-4faa-ae0f-3ed11e9ef407&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083123

---

JOURNAL

JAMA